Although it has not been demonstrated that doses should be reduced if suffering from any renal disease, caution is advised. If this is your case, consult with your doctor before using this medication.
If you estimate that the action of Stesolid is too strong or too weak, inform your doctor or pharmacist.
If you use more Stesolid 10 mg than you should
You may experience symptoms ranging from drowsiness to coma. However, given the administration route, it is unlikely that overdose is possible.
If this occurs, consult your doctor or pharmacist immediately or go to the nearest hospital and bring this leaflet.
In case of overdose or accidental ingestion, contact the Toxicological Information Service, Telephone 91 562 04 20.
If you forgot to use Stesolid 10 mg
Do not use a double dose to compensate for the missed doses.
If you interrupt treatment with Stesolid 10 mg
Your doctor will indicate the duration of your treatment with Stesolid. Do not suspend treatment before or abruptly, as your problem may recur or you may experience other symptoms.
If you stop using the medication abruptly, you may experience the following symptoms: insomnia, headache or muscle pain, anxiety, tension, restlessness, confusion, and irritability. Treatment should be suspended gradually, following the instructions received from your doctor.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Normally, with diazepam-containing medications, side effects have been detected at the beginning of treatment, such as drowsiness, apathy, decreased alertness, confusion, fatigue, headache, dizziness, muscle weakness, lack of coordination, or double vision. These phenomena usually disappear as treatment continues.
Occasionally, other side effects have been reported, such as gastrointestinal disturbances, skin reactions, or changes in sexual desire.
In general, after diazepam administration, the following side effects have been described:
Very common (may affect more than 1 in 10 patients)
Common (may affect between 1 and 10 in 100 patients)
Uncommon (may affect between 1 and 10 in 1,000 patients)
Rare (may affect between 1 and 10 in 10,000 patients)
Very rare (may affect less than 1 in 10,000 patients)
Blood and lymphatic system disorders
Rare: neutropenia (decreased neutrophil count), with prolonged diazepam administration.
Very rare: anemia, pancytopenia (decreased count of all blood elements), decreased platelets.
Immune system disorders
Very rare: allergies
Endocrine disorders
Very rare: Cases of galactorrhea (milk secretion from the nipple) have been described in women with normal prolactin levels in serum and breast enlargement in men taking diazepam regularly.
Benzodiazepines may decrease body temperature, probably in a dose-dependent manner; this effect has been observed in neonates of mothers who took benzodiazepines in the last stages of pregnancy.
Psychiatric disorders
Rare: depression, decreased sexual desire, paradoxical excitement that may lead to: hostility, aggression, and disinhibition, anxiety, hallucinations, insomnia, sleep disturbances. Mild mental alterations: memory loss, slowing of reaction time.
Very rare: difficulty remembering some things.
Nervous system disorders
Very common: drowsiness.
Common: headache, muscle coordination disturbances, dizziness, confusion.
Uncommon: hyperactivity, speech disturbances, tremor.
Rare: convulsions.
Eye disorders
Rare: blurred vision, double vision, involuntary eye movements.
Diazepam has some anticholinergic activity, which could cause pupil dilation and exacerbate narrow-angle glaucoma.
Ear and labyrinth disorders
Uncommon: vertigo.
Cardiac disorders (only described when administered intravenously)
Uncommon: alteration of heart rhythm and inflammation of veins with thrombus formation.
In rapid intravenous administration
Uncommon: thrombus formation in veins, vein inflammation, local irritation, swelling.
Rare: severe blood pressure drop, decreased heart rate, circulatory collapse.
Vascular disorders
Very rare: bullous vasculitis (purple skin eruption due to alteration of small blood vessels).
Respiratory disorders
Common: respiratory depression.
Gastrointestinal disorders
Uncommon: gastrointestinal disturbances, nausea, constipation, salivation disturbances.
Hepatobiliary disorders
Very rare: yellow skin discoloration, elevated liver enzymes.
Skin and subcutaneous tissue disorders
Uncommon: rash and urticaria, sweating, local irritation after rectal administration.
Very rare: described a clinical syndrome that presents with fever, rashes, and blood alterations (Sweet syndrome).
Musculoskeletal disorders
Very rare: in patients with low sodium levels in the blood, muscle pain and weakness may occur, which can be very severe.
Renal and urinary disorders:
Uncommon: urinary retention, incontinence
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use:www.notificaRAM.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not usethis medicationafter the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
No special storage conditions are required.
Medications should not be disposed of through drains or in the trash. Dispose of the packaging and medications you no longer need at the SIGRE collection pointat the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. By doing so, you will help protect the environment.
Composition of Stesolid 10 mg
Appearance of the product and contents of the packaging
Stesolid 10 mg is a transparent, practically colorless solution presented in single-dose vials for rectal administration. Each single-dose vial contains 2.5 ml of rectal solution.
It is presented in cases containing 2 and 5 single-dose vials.
Holder of the marketing authorization
Faes Farma, S.A.
Autonomia Etorbidea, 10
48940 Leioa (Bizkaia)
Spain
Responsible for manufacturing
Faes Farma, S.A.
Maximo Agirre Kalea, 14
48940 Leioa (Bizkaia)
Spain
Last review date of this leaflet: October 2024
The detailed information about this medicine is available on the website of the Spanish Agency of Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.